The association of DM2 with solid tumors, and particularly with HCC (hepatocellular carcinoma), has been long suspected and several studies have reported increased mortality rates for neoplastic diseases in patients with DM2. However, the temporal relationship between onset of diabetes and development of HCC, and the clinical and metabolic characteristics of patients with DM2 and HCC have not been well examined.
A research article to be published on October 7, 2008 in the World Journal of Gastroenterology addresses this question.
The research team led by Dr. Valter Donadon from Pordenone Hospital of Italy investigated the relationships between DM2 and risk of HCC in a large population based case-control study. They enrolled 465 consecutive patients with HCC compared with an age and sex matched control group of 490 subjects.
Their results confirm that patients with DM2 have a significantly increased risk of HCC, independent of cofactors such as HBV and HCV infection and alcohol intake, and demonstrate that DM2 pre-exists to the development of HCC in most cases, suggesting that DM2 is more likely a concourse rather than merely a consequence of the liver tumor. This conclusion is also supported by the finding of a similar frequency and severity of DM2 in patients with small HCC detected during follow-up of cirrhosis and in those with more advanced and diffuse cancers detected outside of a surveillance program.
The observation that patients with DM2, particularly males, treated with insulin had an increased frequency of HCC is intriguing and clinically relevant. These patients are those often showing the highest insulin blood levels, and this might contribute to facilitate the development of HCC.
It is well known that patients with DM2 treated with insulin are those with more severe hyperinsulinemia and more diabetic complications. Their results indicate the need for close surveillance for HCC in patients with chronic liver disease and DM2, particularly when males and treated with insulin. They also suggest that in these patients strategies to improve the metabolic control should be directed primarily against hyperinsulinemia by avoiding as much as possible the use of oral secretagogue drugs and of insulin treatment, giving preference to insulin-sensitizers such as metformin and glitazones. Because diabetes may be secondary to HCC or to the underlying cirrhosis, and the liver cirrhosis may be caused by diabetes, further studies, including cirrhotic patients, must be performed to evaluate these complex relationships and particularly whether the diabetes itself has a direct carcinogenetic effect.
Donadon V, Balbi M , Casarin P, Vario A, Alberti A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: Potential role of insulin. World J Gastroenterol 2008;14(37): 5695-5700 http://www.wjgnet.com/1007-9327/14/5695.asp World Journal of Gastroenterology (WJG),
DID YOU KNOW:
Spices Help Diabetes: If you’ve ever eaten West African cuisine, you may have come across the pungent peppery spice known as grains of paradise or Aframomum melegueta, a member of the ginger family that grows well in the swamps along the coast. It might also be a powerful diabetes treatment. Ilya Raskin, a plant biologist at Rutgers University in New Jersey, has tested an extract of A. melegueta on diabetic mice and says it produces a significant drop in their blood sugar levels. Raskin says the extract could help to prevent the onset of diabetes in people at high risk and could be given prophylactically to individuals who have a family history of diabetes, or have other risk factors for developing such disease. Read the full diabetes spice patent application
Learn about the world’s smallest blood glucose testing system: Introducing TRUE2go™ – no coding, blood glucose testing for your patients on-the-go. New TRUE2go™ joins the new TRUEresult™ no-coding meter. These two systems, with TRUEtest™ strips, better fit your patients’ active lifestyles and make it easier and affordable for them to better manage their diabetes.